Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.38 |
| ▸ | CDK2 | P24941 | 8/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.38 |
| ▸ | MGMT | P16455 | 3/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16037341 | 0.87 | CDK1 (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL9170817 | 0.82 | HPRT1 (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL385152 | 0.82 | HPRT1 (0.38) | HPRT1CYP3A4 | |
| SCHEMBL6751932 | 0.78 | PNP (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL2385930 | 0.77 | ADORA2B (0.50) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL5503610 | 0.76 | CDK1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL16020626 | 0.76 | HPRT1 (0.43) | MGMTHPRT1PNPADORA2B | |
| SCHEMBL9806974 | 0.76 | PNP (0.44) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL15545146 | 0.76 | HPRT1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8921064 | 0.75 | ADORA2B (0.35) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | claimed |
| EP-1831235-B1 | LUNG-TARGETED DRUGS | UNIV CALIFORNIA (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8318700-B2 | Lung-targeted drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2107909-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX Pharmaceuticals, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1831235-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006066074-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-1996009307-A1 | PURINE AND 8-AZAPURINE DERIVATIVES SUITABLE TO THE THERAPEUTIC TREATMENT OF AIDS | ISTITUTO SUPERIORE DI SANITA' (IT) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | CDK1 361/4885CCNB1 1030/4885CCNA2 1024/4885 |
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | CDK1 1683/4885CCNB1 2573/4885CCNA2 3287/4885 |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | DGKG, GK, PHOSPHO1 | CDK1 1683/4885CCNB1 2573/4885CCNA2 3287/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | CDK1 805/4885CCNB1 344/4885CCNA2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.